Trials / Withdrawn
WithdrawnNCT01015521
Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Tigris Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aminoflavone Prodrug | Aminoflavone Prodrug administered D1, D8 of 21-day cycle |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-12-01
- First posted
- 2009-11-18
- Last updated
- 2010-11-03
Source: ClinicalTrials.gov record NCT01015521. Inclusion in this directory is not an endorsement.